Table 3.
Multivariable analysis and major bleeding
| Characteristic | All patients n = 1 070 |
Platelet count < 75 × 103/μL n = 519 |
Platelet count of 75 to 100 × 103/μL n = 551 |
|||
|---|---|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | |
| Age > 65 y | 1.96 (1.08-3.58) | .03 | 3.68 (1.29-10.54) | .01 | 1.31 (0.61-2.83) | .48 |
| Sex∗ | 0.94 (0.59-1.49) | .78 | 1.07 (0.55-2.07) | .84 | 0.85 (0.44-1.64) | .63 |
| Hypertension | 1.36 (0.82-2.26) | .24 | 0.91 (0.43-1.93) | 0.80 | 1.92 (0.96-3.84) | .06 |
| Kidney disease | 1.42 (0.75-2.69) | .28 | 1.49 (0.55-3.99) | .43 | 1.39 (0.59-3.29) | .45 |
| Cancer | 0.66 (0.32-1.35) | .26 | 0.48 (0.16-1.41) | .18 | 0.95 (0.37-2.41) | .91 |
| Prior bleed | 0.94 (0.22-3.93) | .93 | 1.07 (0.14-7.96) | .95 | 0.89 (0.11-7.31) | .92 |
| Thrombocytopenia | 2.20 (1.36-3.58) | .001 | 2.92 (1.45-5.88) | .003 | 1.88 (0.96-3.67) | .07 |
| Anticoagulant† | 1.24 (0.79-1.94) | .35 | 1.23 (0.64-2.36) | .54 | 1.31 (0.7-2.44) | .39 |
| Antiplatelet | 1.28 (0.74-2.24) | .38 | 1.98 (0.81-4.86) | .13 | 0.91 (0.44-1.9) | .80 |
P < .05 was considered statistically significant.
∗
HRs are for the female group as compared with the male group.
†
HRs are for the warfarin group as compared with the direct oral anticoagulant group.